https://www.selleckchem.com/pr....oducts/debio-0123.ht
The participants' responses to treatments were complete remission in 12.5% of (n = 2), partial remission in 31.25% (n = 5), disease stability in 18.7% (n = 3), and disease progression in 37.5% (n = 6). In total, pretreatment and posttreatment Karnofsky Performance Score and Eastern Cooperative Oncology Group scores did not improved (P 0.05). The patients were followed up from 1 month to 26 months (median, 3 months). This preliminary result suggests that peptide receptor radionuclide therapy using 177Lu-DOTATATE may be associated
Curtir
Comentario
Compartilhar
